KR101475311B1 - 항암 활성을 갖는 화합물 - Google Patents

항암 활성을 갖는 화합물 Download PDF

Info

Publication number
KR101475311B1
KR101475311B1 KR1020097023566A KR20097023566A KR101475311B1 KR 101475311 B1 KR101475311 B1 KR 101475311B1 KR 1020097023566 A KR1020097023566 A KR 1020097023566A KR 20097023566 A KR20097023566 A KR 20097023566A KR 101475311 B1 KR101475311 B1 KR 101475311B1
Authority
KR
South Korea
Prior art keywords
amino
dione
delete delete
trifluoromethyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097023566A
Other languages
English (en)
Korean (ko)
Other versions
KR20090128560A (ko
Inventor
타쿠미 카와베
마치요 이시가키
타쿠지 사토
사야카 야마모토
요코 하세가와
Original Assignee
가부시키가이샤 캔버스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 캔버스 filed Critical 가부시키가이샤 캔버스
Publication of KR20090128560A publication Critical patent/KR20090128560A/ko
Application granted granted Critical
Publication of KR101475311B1 publication Critical patent/KR101475311B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020097023566A 2007-04-11 2008-04-11 항암 활성을 갖는 화합물 Active KR101475311B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91125807P 2007-04-11 2007-04-11
US60/911,258 2007-04-11

Publications (2)

Publication Number Publication Date
KR20090128560A KR20090128560A (ko) 2009-12-15
KR101475311B1 true KR101475311B1 (ko) 2014-12-23

Family

ID=39939984

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097023566A Active KR101475311B1 (ko) 2007-04-11 2008-04-11 항암 활성을 갖는 화합물

Country Status (17)

Country Link
US (2) US8084454B2 (cg-RX-API-DMAC7.html)
EP (4) EP4074704A1 (cg-RX-API-DMAC7.html)
JP (2) JP5635396B2 (cg-RX-API-DMAC7.html)
KR (1) KR101475311B1 (cg-RX-API-DMAC7.html)
CN (2) CN101720323A (cg-RX-API-DMAC7.html)
AU (1) AU2008294410B2 (cg-RX-API-DMAC7.html)
BR (2) BR122022005149B1 (cg-RX-API-DMAC7.html)
CA (4) CA2913840C (cg-RX-API-DMAC7.html)
DK (2) DK2152692T3 (cg-RX-API-DMAC7.html)
ES (3) ES2732230T3 (cg-RX-API-DMAC7.html)
HU (2) HUE059861T2 (cg-RX-API-DMAC7.html)
IL (4) IL309201A (cg-RX-API-DMAC7.html)
MX (3) MX2009011025A (cg-RX-API-DMAC7.html)
NZ (1) NZ580237A (cg-RX-API-DMAC7.html)
RU (1) RU2482111C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009031040A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906960B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101720323A (zh) * 2007-04-11 2010-06-02 三井有限公司 具有抗癌活性的化合物
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP2393488B1 (en) * 2009-02-06 2019-06-19 University Of Southern California Therapeutic compositions comprising monoterpenes
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
US8507734B2 (en) 2010-03-03 2013-08-13 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP3173080B1 (en) 2010-08-27 2019-12-11 Neonc Technologies Inc. Pharmaceutical compositions comprising derivatives of perillyl alcohol
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
WO2013169600A1 (en) * 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
HK1207375A1 (en) 2012-06-14 2016-01-29 Daiichi Sankyo Company, Limited Piperidinylpyrazolopyridine derivative
JP2016506921A (ja) * 2013-01-30 2016-03-07 バイエル ファーマ アクチエンゲゼルシャフト アミノ置換イソチアゾール
US9540462B2 (en) 2014-12-05 2017-01-10 Massachusetts Institute Of Technology Catechol-rich polymers from N-substituted maleimides
HRP20230659T1 (hr) * 2015-01-26 2023-10-13 Ottawa Hospital Research Institute Sastavi i metode za osjetljivost na viruse
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
JP2019513700A (ja) 2016-03-16 2019-05-30 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺有害生物剤及び植物保護剤としてのｎ−（シアノベンジル）−６−（シクロプロピル−カルボニルアミノ）−４−（フェニル）−ピリジン−２−カルボキサミド誘導体及び関連する化合物
USD801721S1 (en) 2016-03-31 2017-11-07 Patricia Grayson Briden Spooled item holding device
USD915100S1 (en) 2016-03-31 2021-04-06 Ocean 22, Llc Spooled item holding device
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
US12419832B2 (en) 2018-01-29 2025-09-23 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
AU2019215707A1 (en) 2018-02-02 2020-07-09 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors
DK3749291T3 (da) 2018-02-08 2024-04-08 Univ Southern California Fremgangsmåder til permeabilisering af blod-hjerne-barrieren
CN115916789B (zh) 2020-05-22 2025-06-27 勃林格殷格翰国际有限公司 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法
WO2021233882A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
US20250017889A1 (en) * 2021-10-15 2025-01-16 The Curators Of The University Of Missouri Inhibitors of p1b-type atpases
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途
CN120247782B (zh) * 2025-06-04 2025-08-19 北京颖泰嘉和生物科技股份有限公司 氟吡菌酰胺类化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5564557A (en) * 1978-11-08 1980-05-15 Mitsui Toatsu Chem Inc Diphenyl ether compound and herbicide containing the same
IL81307A0 (en) * 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5635966A (en) * 1994-01-11 1997-06-03 Hewlett-Packard Company Edge feed ink delivery thermal inkjet printhead structure and method of fabrication
JPH07224032A (ja) * 1994-02-09 1995-08-22 Mitsui Petrochem Ind Ltd Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤
JPH07244032A (ja) * 1994-03-01 1995-09-19 Ishikawajima Harima Heavy Ind Co Ltd 溶接部検査装置
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2245029A1 (en) * 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6205557B1 (en) 1998-06-09 2001-03-20 At&T Corp. Redundant call processing
US6476061B1 (en) * 1998-11-24 2002-11-05 Basf Aktiengesellschaft Fungicides containing pyrrolidones as their active agents
WO2001021771A2 (en) 1999-09-22 2001-03-29 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
EP1257172B1 (de) * 2000-02-26 2004-10-13 Basf Aktiengesellschaft Fungizide mittel enthaltend als wirkstoffe pyrrolidone und deren verwendung bei der behandlung von pflanzen
JP2002318434A (ja) * 2001-04-23 2002-10-31 Konica Corp ハロゲン化銀写真感光材料、処理方法、および画像形成方法
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003247044B8 (en) * 2002-06-06 2009-04-09 Canbas Co. Ltd. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA-damaging treatments
US7572816B2 (en) * 2003-08-01 2009-08-11 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
JP3977411B2 (ja) * 2004-03-10 2007-09-19 株式会社クレハ アミン系塩基性化合物とその用途
JP2008502595A (ja) * 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
CN101115724A (zh) * 2005-02-08 2008-01-30 默克公司 关卡激酶抑制剂
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
EP1960386A2 (en) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2007114338A1 (ja) * 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
CN101720323A (zh) 2007-04-11 2010-06-02 三井有限公司 具有抗癌活性的化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes

Also Published As

Publication number Publication date
CA2684037A1 (en) 2009-03-12
CA3030510A1 (en) 2009-03-12
BR122022005149B1 (pt) 2022-09-27
IL289165B2 (en) 2024-05-01
HK1139143A1 (zh) 2010-09-10
DK2152692T3 (en) 2016-09-26
EP2152692B1 (en) 2016-06-15
RU2482111C2 (ru) 2013-05-20
ZA200906960B (en) 2010-12-29
US20110092514A1 (en) 2011-04-21
JP5635396B2 (ja) 2014-12-03
CN101720323A (zh) 2010-06-02
ES2927954T3 (es) 2022-11-14
DK3567035T3 (da) 2022-09-05
EP3567035A1 (en) 2019-11-13
US8084454B2 (en) 2011-12-27
EP3088397B1 (en) 2019-04-10
EP2152692A2 (en) 2010-02-17
CA2913840C (en) 2019-03-05
RU2009141619A (ru) 2011-05-20
IL289165B1 (en) 2024-01-01
IL242883B (en) 2022-01-01
JP2014012706A (ja) 2014-01-23
MX374896B (es) 2025-03-04
CN105175394A (zh) 2015-12-23
ES2594704T3 (es) 2016-12-22
US8415357B2 (en) 2013-04-09
US20080275057A1 (en) 2008-11-06
AU2008294410B2 (en) 2012-09-06
CN105175394B (zh) 2018-06-08
HUE059861T2 (hu) 2023-01-28
IL289165A (en) 2022-02-01
BRPI0810911B1 (pt) 2022-05-17
CA3030510C (en) 2023-03-14
MX2020009403A (es) 2022-03-31
KR20090128560A (ko) 2009-12-15
WO2009031040A2 (en) 2009-03-12
JP2010523644A (ja) 2010-07-15
AU2008294410A1 (en) 2009-03-12
EP3088397A1 (en) 2016-11-02
WO2009031040A3 (en) 2009-05-14
BRPI0810911A2 (pt) 2021-03-30
EP4074704A1 (en) 2022-10-19
EP2152692B9 (en) 2020-03-25
HUE029370T2 (hu) 2017-02-28
CA2684037C (en) 2016-02-16
IL201380A0 (en) 2010-05-31
MX2009011025A (es) 2010-01-25
EP3567035B1 (en) 2022-06-01
CA2913840A1 (en) 2009-03-12
ES2732230T3 (es) 2019-12-12
NZ580237A (en) 2012-06-29
MX391154B (es) 2025-03-21
IL309201A (en) 2024-02-01
CA3188320A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
KR101475311B1 (ko) 항암 활성을 갖는 화합물
CN101784543B (zh) 作为细胞坏死抑制剂的吲哚和吲唑化合物
WO2020156243A1 (zh) Shp2抑制剂及其应用
WO2020156242A1 (zh) Shp2抑制剂及其应用
WO2018177403A1 (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2015158310A1 (zh) 一种酪氨酸激酶抑制剂及其用途
CN114057771A (zh) 大环化合物及其制备方法和应用
WO2022156758A1 (zh) 新型酰胺吡咯类化合物及其在药物中的用途
CN105636956B (zh) 作为细胞坏死阻碍剂的吲哚化合物
HK40083024A (en) Quinoline compounds with anti-cancer activity
HK1139143B (en) Compounds with anti-cancer activity
HK40039964A (en) Tricyclic compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091111

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120831

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140123

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140823

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140922

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140823

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20141111

Appeal identifier: 2014101005879

Request date: 20140922

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140922

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140922

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140327

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20120831

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20141111

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20141024

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141216

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141217

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20171208

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20171208

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20181207

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20181207

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20191206

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20191206

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20201204

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20201204

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20211203

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20211203

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20221027

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20221027

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 11

End annual number: 11